🏥Shimadzu Corporation signs a collaborative research agreement with the National Cancer Institute with measurement technology on cancer immunotherapy 2018/01/15

By Cancer, Medical science

🏥Shimadzu Corporation signs a collaborative research agreement with the National Cancer Institute with measurement technology on cancer immunotherapy 2018/01/15

Shimadzu Corporation has concluded a five-year CRADA * (collaborative research and development contract) with the National Cancer Institute (NCI) belonging to the National Institute of Health in the United States and is planning to introduce a new We will jointly conduct research and development on measurement technologies for evaluating and improving the safety and therapeutic efficacy of the cancer treatment method “Near Infrared Photoimmunotherapy (NIR-PIT)”.

2018 | News | Shimadzu Corporation

https://www.shimadzu.co.jp/news/press/n00kbc000000ewp9.html

More from tokioX :

  1. CiRA: Developed universal iPS cells: Cancer immunotherapy
  2. Hokkaido University: Developed 2-axis CBCT / 4D CBCT function: High-precision proton beam therapy
  3. Cancer treatment: Boron neutron capture therapy/BNCT treatment start: Developed by Kyoto University/Sumitomo Heavy Industries
  4. Sumitomo Heavy Industries: World’s first accelerator / BNCT treatment system approval: for head and neck cancer
  5. TIT:PVA with BPA through reversible boronate esters in aqueous solution
  6. Hitachi: US Sibley Memorial Hospital, proton beam cancer treatment started: latest ‘spot scanning’
  7. Cancer Therapy: Kyoto University, New Method Detecting Aggressively Attacking Cancer Cells – Human iPS-derived “Killer T Cells”